12:33 PM EDT, 10/17/2024 (MT Newswires) -- Nektar Therapeutics ( NKTR ) shares were up nearly 5% in recent trading Thursday after results from an early-stage study of NKTR-255 found the treatment benefited patients with a type of blood cancer.

According to Nektar, the medicine was found to increase the 12-month relapse free survival of subjects from 38% to 67% when added to CD19-22 CAR-T cell therapy.

Nektar's drug was being evaluated in subjects with relapsed or refractory B-cell acute lymphoblastic leukemia.

The company said that eight of the nine patients in the phase 1 clinical trial achieved complete remission.

Results from the study were published in Blood, a peer-reviewed medical journal of the American Society of Hematology, the company added.

Price: 1.45, Change: +0.07, Percent Change: +4.71